I do want to have a open discussion on the "IMU internal conversation" given now the beautiful data from Her-vass validates entire b-cell platform including those combo, IDMC feedback, fundings and many many more to take in consideration.
Maybe
Reduce the patient numbers per IDMC to fast-track the trails
or
Keep the current study to play safe on FDA approval perspective
or
Sell it to bigpharm for funding and focus on the combination and CF33
or
.
.
.
What would you do if you are LC/PH?
I do want to have a open discussion on the "IMU internal...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
